| Officer | Age | In this role | Source |
|---|---|---|---|
|
Niels Riedemann
Also a director
Executive Director and Chief Executive Officer
|
54 | Not stated | |
|
Thomas Taapken
Chief Financial Officer
|
60 |
Since 2020
6 years
|
|
|
Renfeng Guo
Also a director
Executive Director and Chief Scientific Officer
|
55 | Not stated | |
|
Camilla Chong
Chief Medical Officer
|
60 |
Since 2023
3 years
|
|
|
Derval O’Carroll
Senior Vice President, Global Head of Regulatory Affairs and Compliance
|
60 | Not stated |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Related-party transactions come from the company’s proxy statement. InflaRx N.V. has not filed one with the SEC.
Loading...